UroGen Pharma to Participate at Upcoming Investor Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (URGN) will be presenting at the Guggenheim 6th Annual Biotechnology Conference and Oppenheimer 34th Annual Healthcare Life Sciences Conference in February 2024. The company aims to showcase its innovative solutions for treating urothelial and specialty cancers. The presentations will be available via webcast, and a replay will be accessible for approximately 90 days.

– Guggenheim 6th Annual Biotechnology Conference –

– Oppenheimer 34th Annual Healthcare Life Sciences Conference –

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in February:

Guggenheim 6th Annual Biotechnology Conference – February 7-8, 2024
Fireside Chat: February 8, 2024 at 11:00 AM ET
Format: 1x1 meetings
Location: New York, NY
Webcast Link: https://guggenheim.metameetings.net/events/guggenheimbiotech24/sessions/50270-urogen-pharma-ltd/webcast

Oppenheimer 34th Annual Healthcare Life Sciences Conference – February 13-14, 2024
Presentation: February 13, 2024 at 12:00 PM ET
Format: Virtual
Webcast Link: https://wsw.com/webcast/oppenheimer33/register.aspx?conf=oppenheimer33&page=urgn&url=https://wsw.com/webcast/oppenheimer33/urgn/2806968

A webcast from both conferences will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201163986/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma Ltd. (URGN) be presenting at the Guggenheim 6th Annual Biotechnology Conference?

UroGen Pharma Ltd. (URGN) will be presenting at the Guggenheim 6th Annual Biotechnology Conference on February 7-8, 2024.

What is the format of the presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference will be virtual and take place on February 13, 2024 at 12:00 PM ET.

Where can the webcast of the conferences be accessed?

The webcast of the conferences will be available via the Investors section of UroGen’s website, www.urogen.com.

For how long will the replay of the webcast be available?

A replay of the webcast will be available for approximately 90 days.

What is the focus of UroGen Pharma Ltd. (URGN) in the conferences?

UroGen Pharma Ltd. (URGN) aims to showcase its innovative solutions for treating urothelial and specialty cancers at the conferences.